News: Hospira Inc (HSP.N)
Mon, Oct 21 2013
HELSINKI, Oct 21 - Orion Oyj : * Orion and Hospira signed a license agreement to continue licensing agreement on sedative agent Precedex in markets outside Europe (Reporting by Helsinki Newsroom)
AUSTIN, Texas - A Texas man who stabbed another man to death when he failed to pay back a $100 debt to an exotic dancer is scheduled to be executed on Thursday.
(Corrects in paragraph 14 drug company name to Hospira Inc from Lundbeck LLC and in paragraph 15 corrects name to Lundbeck from Hospira)
(Corrects in paragraph 13 drug company name to Hospira Inc from Lundbeck LLC and in paragraph 14 corrects name to Lundbeck from Hospira)
LONDON/ZURICH June 28 - European regulators have cleared the way for the first serious threat to the makers of multibillion-dollar biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis.
- Hospira Inc. - Analyst/Investor Day
- 5 Big Trades to Take for a Fed Taper
- Hospira Incorporated: Unappreciated Upside Due To A Promising Biosimilar Pipeline
- Hospira Management Discusses Q3 2013 Results - Earnings Call Transcript
- Hospira, Inc. Discusses Q3 2013 Results (Webcast)
- Roche: Impact Of Rituxan Patent Expiration In Europe
- FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira
- Hospira to Present at the J.P. Morgan 32nd Annual Healthcare Conference Jan. 15, 2014
- Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance, and Celsion
- Updated Financial Standings, Company Announcements, and Upcoming Investors Conferences - Research Report on Zimmer, Boston Scientific, Hospira, Elan, and Incyte
- Events, Marketing Recommendation, FDA Meeting, and Marketing Authorization - Research Report on Hospira, Novo Nordisk, Repros Therapeutics, GW Pharmaceuticals, and Envision Healthcare
- Hospira to Host 2013 Investor Day
- Approved Acquisition, FDA Approvals, Senior Note Offerings, and Announcements by Drug Delivery Companies - Research Report on Elan, IntelliPharmaCeutics, Valeant Pharmaceuticals, Hospira, and Alkermes
- Before the Bell Scans: Theravance Inc., Alkermes PLC, Celsion Corp., and Hospira Inc.
- Financial Results, Regulatory Approval, Stock Price Update, and Conference Participation - Research Report on Hologic, Edwards Lifesciences, Hospira, PAREXEL, and Sirona
- Hospira Reports Third-Quarter 2013 Results